WuXi XDC and Multitude Therapeutics announced that they have reached a comprehensive partnership in drug-linker technology, which is co-developed with HySlink Therapeutics (HySlink), and CRDMO services spanning from discovery to commercialization. WuXi XDC signed a Memorandum of Understanding (MOU) with HySlink on the same day. WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services.

As WuXi XDC's strategic partner, Multitude Therapeutics will provide proprietary T-Moiety linker technologies, co-developed with HySlink. Both parties will synergize their strengths to build more efficient ADC technology in terms of novel T-moiety linkers, camptothecin derivative conjugation and high DAR value, among others. This platformization of new technologies will enable our clients to accelerate the discovery of preclinical ADC candidates (PCCs) and develop more novel bioconjugates; and improve the development efficiency and rate of success.